{"entity":{"id":"nct06357533","kind":"trial","name":"Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥","aka":["TROPION-Lung10"],"tldr":"A phase 3 trial of Datopotamab deruxtecan, Rilvegostomig, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, now recruiting.","summary":"Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations. ClinicalTrials.gov record last updated 2026-09-23: recruiting. Enrollment is planned at 675 participants. Primary completion is estimated at 2029-12-28. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Datopotamab Deruxtecan, Rilvegostomig, Pembrolizumab. Registered primary measures: Progression-Free Survival (PFS) in TROP2 biomarker positive participants.; Overall Survival (OS) in TROP2 biomarker positive participants..","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06357533","url":"https://clinicaltrials.gov/study/NCT06357533"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","pdl1-high-nsclc"],"sections":[],"technologies":["adc","checkpoint-inhibitor","topoisomerase-inhibitors"],"targets":["trop2"],"drugs":["datopotamab-deruxtecan","rilvegostomig","pembrolizumab"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2026-09-23: recruiting. Enrollment is planned at 675 participants. Primary completion is estimated at 2029-12-28. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT06357533","phase":"3","setting":"Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations","sponsor":"AstraZeneca","participation":[{"nct":"NCT06357533","source":"https://clinicaltrials.gov/study/NCT06357533","fetchedAt":"2026-10-07T16:54:34.595Z","studySha256":"8588e806c52b743f6481119b9cf18b7694443f14b79bf7ab682f02d5f0c50c68","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-23","leadSponsor":"AstraZeneca","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":675,"enrolmentType":"ESTIMATED","siteCount":289,"recruitingSiteCount":235,"countries":["Australia","Austria","Belgium","Brazil","Canada","China","Germany","Hungary","India","Italy","Japan","Poland","Puerto Rico","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","United States","Vietnam"]}],"started":"2024-04-11","startedType":"actual","enrolled":675,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06357533/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pdl1-high-nsclc","kind":"cancer","name":"PD-L1-high non-small-cell lung cancer without a driver mutation","route":"/cancers/pdl1-high-nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"rilvegostomig","kind":"drug","name":"Rilvegostomig","route":"/drugs/rilvegostomig/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}